Document is current
Any future updates will be listed below
-
Authors
Louis, Gilles
Pétré, Benoit
Sousa-Pinto, Bernardo
Bousquet, Jean
Van Ganse, Éric
Schleich, Florence
Louis, Renaud
-
Funding
Funding for this research was provided by:
Belgian Federal Science Policy Office (EOS O.001422, EOS 0013618F)
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 28 November 2024
First Online: 2 December 2024
Declarations
:
: Outside of this submitted work, RL received unrestricted research grants from GSK, AstraZeneca, Novartis and Chiesi and lecture or adboard fees from GSK, AZ, Novartis and Sonafi. Outside of this submitted work, FS received lecture or adboard fees from Chiesi, AZ, GSK, and Novartis. Outside this submitted work, JB reports personal fees (member of advisory boards, consultations, honoraria for meeting lectures) from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi‐Aventis, Teva, Uriach. Shareholder of KYomed Innov and MASK-air-SAS. The rest of the authors declare that they have no relevant conflicts of interest.
: The Study was approved by the CHU Liège ethics committee. Signed informed consent was obtained from patients as soon as they entered the asthma clinic of the CHU Liège. They agreed that their clinical data and the health outcomes they reported in the routine setting would be used for the purposes of research.
